Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to…
Roche announced that Tecentriq SC (atezolizumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. It will be provided by the…
Read More...
Read More...